Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR610 in solid tumors and NSCLC
NCT01631279Phase 2Terminated
- Sponsor
- Proacta Inc.
- Start
- Aug 2012
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tarloxotinib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Proacta Inc.. Started Aug 2012; status: terminated.
02
Drugs
tarloxotinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01631279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01631279.